{"id":"NCT01401361","sponsor":"Abbott Medical Devices","briefTitle":"Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System","officialTitle":"Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10","primaryCompletion":"2012-04","completion":"2012-09","firstPosted":"2011-07-25","resultsPosted":"2013-12-23","lastUpdate":"2019-02-15"},"enrollment":150,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Typical Atrial Flutter"],"interventions":[{"type":"DEVICE","name":"Treatment Arm","otherNames":["Ablation with Contact Therapy Cool Path system"]}],"arms":[{"label":"Treatment Arm","type":"EXPERIMENTAL"}],"summary":"To demonstrate that the use of Contact Therapy™ Cool Path™ ablation catheter in conjunction with the EnSite Velocity Contact Technology for the treatment of typical atrial flutter\n\n* Does not result into unacceptable risk of intra-procedural composite serious adverse events and,\n* Does not affect efficacy of the ablation procedure The study will also evaluate the","primaryOutcome":{"measure":"Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure","timeFrame":"7 days","effectByArm":[{"arm":"Treatment Arm","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":20,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":134},"commonTop":["Arrhythmia"]}}